All In Biotech

Drug Trial Radar · NCT02689284

Combination Margetuximab and Pembrolizumab for Advanced, Metastatic HER2(+) Gastric or Gastroesophageal Junction Cancer

A Phase 1b/2, Open Label, Dose Escalation Study of Margetuximab in Combination With Pembrolizumab in Patients With Relapsed/Refractory Advanced HER2+ Gastroesophageal Junction or Gastric Cancer

Last checked: Nov 20, 2026Latest source record: Mar 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

95

Actual

Start

Jan 2016

Primary completion

Jan 2021

Study completion Jan 2021

Sponsor

Lead sponsor
MacroGenicsIndustry
Sponsor type
Industry
Collaborators
Merck Sharp & Dohme LLC
First posted
Feb 23, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This main purpose of this clinical study is to learn about the safety and activity of margetuximab and pembrolizumab combination treatment in patients with HER2+ gastric and gastroesophageal junction cancer.

Conditions

  • Gastric Cancer
  • Stomach Cancer
  • Esophageal Cancer

Interventions

  • Margetuximab 10 mg/kgBiological

    Margetuximab treatment is administered intravenously (IV) once every 21-day cycle

  • Margetuximab 15 mgBiological

    Margetuximab treatment is administered IV once every 21-day cycle

  • PembrolizumabBiological

    Pembrolizumab treatment is administered IV once every 21-day cycle

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Patients With Dose Limiting ToxicitiesTime frame: 21 days
  2. Number of Patients With Adverse Events (AEs) and Serious Adverse Events (SAEs).Time frame: up to 24 months
  3. Number of Patients With a Complete Response (CR) or Partial Response (PR) to TreatmentTime frame: 12 months
  4. Number of Patients With a Complete Response (CR) or Partial Response (PR) to Treatment Using irRC CriteriaTime frame: 12 Months
  5. Duration of ResponseTime frame: up to 24 months

Locations

28 sites in 5 countries. Site status is shown where the registry gives one.

  • Yale School of Medicine

    New Haven, Connecticut

  • Georgetown University-Lombardi Comprehensive Cancer Center

    Washington D.C., District of Columbia

  • University of Chicago

    Chicago, Illinois

  • Johns Hopkins University Medical Center

    Baltimore, Maryland

  • Dana-Farber Cancer Institute/Harvard University Medical Center

    Boston, Massachusetts

  • Karmanos Cancer Institute

    Detroit, Michigan

  • Washington University School of Medicine

    St Louis, Missouri

  • Duke University Medical Center

    Durham, North Carolina

  • Fox Chase Cancer Center

    Philadelphia, Pennsylvania

  • Sarah Cannon Research Institute

    Nashville, Tennessee

  • Swedish Cancer Institute

    Seattle, Washington

  • Juravinski Cancer Centre - McMaster University

    Hamilton, Ontario, Canada

  • McGill University Health Centre

    Montreal, Quebec, Canada

  • National Cancer Centre

    Singapore, Singapore

  • National University Hospital

    Singapore, Singapore

  • Raffles Hospital

    Singapore, Singapore

  • Kyungbuk National University Hospital

    Daegu, South Korea

  • Gachon University Gil Medical Center

    Incheon, South Korea

  • Chonbuk National University Hospital

    Seoul, South Korea

  • Asan Medical Center

    Seoul, South Korea

  • Korea University Anam Hospital

    Seoul, South Korea

  • Korea University Guro Hospital

    Seoul, South Korea

  • Samsung Medical Center

    Seoul, South Korea

  • Seoul National University Bundang Hospital

    Seoul, South Korea

  • Seoul National University Hospital

    Seoul, South Korea

  • National Taiwan University Hospital

    Taipei, Taiwan

  • Taipei Veterans General Hospital

    Taipei, Taiwan

  • Tri-Service General Hospital

    Taipei, Taiwan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.